ClinicalTrials.gg
CompletedNCT01986894QT/QTcUpdated Nov 12, 2019

A Phase 1 QT Study in Healthy Male Subjects

A Phase 1 interventional study of Placebo and Pomalidomide in Clinical Pharmacology, Healthy Volunteer Study, sponsored by Celgene. Completed at 1 site in United States. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This is a single-center, randomized, double-blind crossover study with four treatments, four periods and four sequences to investigate the effects of orally administered pomalidomide on QT interval. The study will be conducted in healthy male subjects. Pomalidomide (clinically indicated dose for multiple myeloma [MM] as per the United States Package Insert [USPI] of 4 mg and supratherapeutic dose of 20 mg) and placebo treatments will be double-blinded. Moxifloxacin (positive control) will be administered in an open-label fashion to determine the sensitivity of the assay. The core electrocardiogram (ECG) laboratory and ECG readers will be blinded to all study treatments and sequences.

Read the detailed description

A total of 72 male subjects will be randomized and enrolled, with 18 subjects assigned to each treatment sequence. For each treatment sequence, each subject will participate in a screening phase, four baseline phases, four treatment periods and a follow up visit. Within 28 days prior to Period 1 dosing, subjects will sign an informed consent document (ICD) and undergo screening procedures to confirm eligibility. Qualifying subjects will return to the clinical site on Day -2 of Period 1 to begin baseline assessments, and will be domiciled at the clinical site from Day -2 to Day 2 of Period 1. For all remaining study periods, subjects will return to the clinical site on Day -1 to begin baseline assessments, and will be domiciled at the clinical site from Day -1 to Day 2. Subjects will be assigned randomly to one of four treatment sequences and will receive a single dose of the assigned treatment on Day 1 of each study period. There will be a minimum of 7 days and no more than 14 days between each dose.

Subjects will begin an overnight fast of at least 8 hours prior to the start of continuous Holter monitoring on Day 1 (and Day 1 in Period 1). On the morning of Day 1 (and Day -1 in Period 1), continuous Holter monitoring for approximately 24 hours will be performed. Triplicate ECGs will be extracted for analysis at specific predose and postdose timepoints (or equivalent times on Day -1 of Period 1). Blood samples will be collected at pre specified timepoints for pharmacokinetic (PK) and clinical laboratory assessments. Safety will be monitored throughout the study.

During each study period, subjects will be discharged from the clinical site on Day 2 upon satisfactory safety review and completion of the required study procedures. A safety follow up will be conducted by telephone 5 to 7 days following discharge in Period 4. In the event that a subject discontinues from the study, an early termination visit will be performed.

02

Conditions studied

  • Clinical Pharmacology, Healthy Volunteer Study

Keywords

  • TQT
  • Pharmacokinetic
  • Healthy
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Must understand and voluntarily sign a written (ICD) prior to any study related procedures being performed.

      1. Must be able to communicate with the Investigator, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules 3. Healthy male of any race between 18 to 50 years of age (inclusive) at the time of signing the ICD, and in good health as determined by a physical exam (P)E.
      1. Must practice true abstinence* or agree to use a condom during sexual contact with a pregnant female or a female of (FCBP) while participating in the study, during dose interruptions and for at least 28 days following study drug discontinuation, even if he has undergone a successful vasectomy.
  • True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. Period abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) and withdrawal are not acceptable methods of .

    1. Must have a body-mass index () between 18 and 30 kg/m2 (inclusive). 6. Clinical laboratory tests must be within normal limits or acceptable to the Investigator.
    1. Subject must be afebrile, with supine systolic blood pressure (BP): 90 to 140 mmHg, supine diastolic BP: 60 to 90 mmHg, and pulse rate (PR): 40 to 110 bpm.

At screening: After the supine measurements, when BP and pulse rate are measured again after 5 minutes of standing, there shall be no more than a 20 mmHg drop in systolic BP or no more than a 10 mmHg drop in diastolic BP and/or no more than a 20 bpm increase in pulse rate associated with clinical manifestation of postural hypotension.

  1. Must have a normal or clinically acceptable 12-lead (ECG) at screening; must have a value ≤ 430 msec.
  1. Must agree to refrain from donating sperm or semen while participating in this study and for at least 28 days following the last dose of study drug.
  1. Must agree to refrain from donating blood or plasma (other than for this study) while participating in this study and for at least 28 days following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

    1. History of any and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular (including hypertension, atherosclerosis, heart failure, supraventricular or ventricular arrhythmias and stroke [Cerebral Vascular Accident (CVA)] or [TIA]), psychological, pulmonary (including asthma and [COPD], treated or not treated), metabolic, endocrine, hematological, allergic disease, drug allergies, known to a member of the class of IMiDs®, known hypersensitivity to moxifloxacin or other major disorders.

      1. Any condition which places the subject at unacceptable risk if he was to participate in the study, or confounds the ability to interpret data from the study.
      1. Have a first degree relative (parent, sibling, child) with Long Syndrome. 4. A level of less than 12.0 g/dL. 5. Abnormal (ECG) findings as follows:
      • Heart rate \< 40 or > 110 bpm, after resting in the supine position for 5 minutes;
      • Pulse rate (PR) interval > 220 msec;
      • QRS interval > 120 including any degree of bundle branch block;
      • QTcF \< 300 or > 430 msec;
      • Evidence of pre-excitation (e.g., Wolfe-Parkinson-White syndrome);
      • Cardiac pacemaker;
      • Atrial fibrillation / flutter. 6. QRS and/or T wave that the Investigator judges to be unfavorable for consistently accurate QT measurements (e.g., indistinct QRS onset, low amplitude T wave, inverted or terminally inverted T wave, merged T/U waves, indistinct T wave offset, or prominent U wave that affects QT measurement).

        1. Neuromuscular artifact that cannot readily be eliminated. 8. Subjects with hypokalemia and/or hypomagnesemia condition. 9. Used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 30 days of the first dose administration, unless sponsor agreement is obtained.
        1. Used any non-prescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration, unless sponsor agreement is obtained.
        1. Has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism and excretion (ADME), e.g., bariatric procedure. Appendectomy and cholecystectomy are acceptable.
        1. Donated blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
        1. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years before dosing, or positive drug test reflecting consumption of illicit drugs.
        1. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before dosing, or positive alcohol screen.
        1. Known to have serum hepatitis or known to be a carrier of surface antigen (HbsAg) or virus antibody (HCV Ab), or have a positive result to the test for (HIV) antibodies at screening.
        1. Exposed to an drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer).
        1. Cotinine level at screening or on Day 2 of Period 1 indicates subject is a moderate or heavy smoker.
        1. History of autonomic dysfunction (e.g., history of fainting or orthostatic hypotension).
        1. Subjects who are part of the clinical staff personnel or family members of the clinical site staff.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Placebo comparator
    Treatment 1 (placebo)

    Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1

    Drug: Placebo

  • Experimental
    Treatment 2 (4 mg pomalidomide)

    Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1

    Drug: Pomalidomide

  • Experimental
    Treatment 3 (20 mg pomalidomide)

    Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1

    Drug: Pomalidomide

  • Active comparator
    Treatment 4 (moxifloxacin)

    One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1

    Drug: Moxifloxacin

Interventions

  • DrugPlacebo

    Single oral dose of Placebo

  • Single oral dose of 4 mg pomalidomide

    Also known as: POMALYST®

  • Single oral dose of 20 mg pomalidomide

    Also known as: POMALYST®

  • Single oral dose of 400 mg moxifloxacin tablet

    Also known as: AVELOX®

06

What researchers measure

Primary outcomes

  1. Time matched, baseline corrected change from placebo of QTcF

    To evaluate the effect of pomalidomide on the time matched changes from placebo in the baseline adjusted QT interval of the electrocardiogram (ECG) using the Fridericia correction method (QTcF)

    Time frame: From before dosing until 23 hours after dosing

  2. Categorical analyses on ECG intervals and changes in ECG morphology

    Time frame: From before dosing until 23 hours after dosing

Secondary outcomes

  1. Time matched, baseline corrected changes from placebo of other ECG intervals (RR, PR, QRS) and categorical analyses on ECG intervals and changes in ECG morphology

    To evaluate the change from placebo in selected ECG parameters (heart rate, PR interval, QRS interval, uncorrected QT interval and morphological patterns) following pomalidomide treatment

    Time frame: From before dosing until 23 hours after dosing

  2. Safety

    To assess the safety and tolerability of single oral doses of pomalidomide

    Time frame: 2 months (from screening visit until end of study

  3. Pharmacokinetics - Cmax

    Maximum observed plasma concentration

    Time frame: From before dosing until 32 hours after dosing

  4. Pharmacokinetics - Tmax

    Time to Cmax

    Time frame: From before dosing until 32 hours after dosing

  5. Pharmacokinetics - AUCinf

    Area under the plasma concentration time curve from time zero extrapolated to infinity

    Time frame: From before dosing until 32 hours after dosing

  6. Pharmacokinetics - AUCt

    Area under the plasma concentration time curve from time zero to the last quantifiable concentration

    Time frame: From before dosing until 32 hours after dosing

  7. Pharmacokinetics - t1/2

    Terminal phase elimination half-life

    Time frame: From before dosing until 32 hours after dosing

  8. Pharmacokinetics - CL/F

    Apparent total plasma clearance when dosed orally

    Time frame: From before dosing until 32 hours after dosing

  9. Pharmacokinetics - Vz/F

    Apparent total volume of distribution when dosed orally, based on the terminal phase

    Time frame: From before dosing until 32 hours after dosing

07

Study locations

1 site
  • PPD Phase I Clinic
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2013 to primary completion in Dec 2013, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2013
First posted
Nov 19, 2013
StartActual
Oct 18, 2013
Primary completionActual
Dec 2, 2013
CompletionActual
Dec 2, 2013
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01986894
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 19, 2013
Start date
Oct 18, 2013
Primary completion
Dec 2, 2013
Completion
Dec 2, 2013
Last update
Nov 12, 2019

Study contacts

Edward O'Mara, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion